Valproic acid (VPA) improved olfactory dysfunction in APP/PS1 transgenic mice of Alzheimer's disease.
The mechanisms relied on the reduced amyloid β (Aβ) burden and ameliorated degenerative changes in the olfactory epithelium (OE) and olfactory bulb (OB).
VPA may provide a new therapeutic strategy for the treatment of olfactory dysfunction in AD patients.